AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (845)	10/11/1997 7:21:00 PM
From: D.Right	of 2173

Dear Henry: I don't know where did you get your numbers. For Rezulin, WLA said in its news release "The average HbA1c reduction for the combination of Rezulin-Sulfonylurea patients was 2.7 percentage points compared to micronized blyburide alone and the averge reduction for the Rezulin-insulin combination patients was 1.3 percentage points compared to insulin alone". The drug Rezulin alone has a 1.3% reduction. Again, pramlintide had an effect of .38% and .39% in six months for type II diabetes, but insulin dosing was not controlled. If it can get to the sub 1% range in its on-going trials as demontstrated in all previous clinical IIs, pramlintide will have a treatment efficiency close to Rezulin. Because pramlintide is working via a different mechanism from Rezulin, it does not have to compete with it. The two can be used together in type II. If Rezulin and pramlintide can work the HbA1c level all the way down to less than 7%, let's forget about the LGND drug (just kidding). Try not to post when you are really sleepy, otherwise, 3% and 1.3% will look the save to you. I don't think you want to mislead other people here on the AMLN thread. Good luck D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next